Georgia's Online Cancer Information Center

Find A Clinical Trial

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (QUINTESSENTIAL-2)

Status
Active
Cancer Type
Multiple Myeloma
Trial Phase
Phase III
Eligibility
18 Years and older, Male and Female
Study Type
Treatment
NCT ID
NCT06615479
Protocol IDs
CA088-1007 (primary)
NCI-2025-00729
Study Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Summary

The purpose of this study is to compare the efficacy and safety of BMS-986393 versus
standard regimens in adult participants with Relapsed or Refractory and
Lanalidomide-refractory Multiple Myeloma.

Eligibility

  1. Participants must have relapsed or refractory multiple myeloma (RRMM).
  2. Participants must have received at least 1 but no greater than 3 prior multiple myeloma (MM) regimens which may include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody, and be refractory to lenalidomide (LEN) (progression on or within 60 days of completing LEN therapy).
  3. Participants must have a documented diagnosis of MM as per International Myeloma Working Group Criteria.
  4. Participants must have measurable disease during screening.
  5. Participants must have adequate organ function.
  6. Participants must have an Eastern Cooperative Oncology group performance status 0 or 1.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University


1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.